Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Canadian Lung Association Research Studentship

Université Laval

$17,500.00

Functional characterization of neutrophils in cystic fibrosis: clinical implications

EF 2022-23

Résumé
Our findings will provide much needed knowledge on an aspect of CF that is not well understood. It will improve our understanding of CF by revealing how the two new types of neutrophils we discovered could be involved in the disease. Also, this research will provide information about how the new drug Trikafta affects the ability of neutrophils to function which is important to fight lung infections in CF. Cystic fibrosis (CF) is the most common fatal genetic disease in children and adults in Canada. It is caused by a change in a region of our genetic material called CFTR. This change affects the CFTR protein that our body needs to make thin and slippery fluids in the lung and other organs, and increases the chances of lung infections. Another reason why CF patients suffer from lung infections is that one of the cells of our body that fights infection does not work properly. We call this cell the neutrophil. These cells are sent to the lung in large numbers during an infection to eliminate the pathogen. While these cells go to the lung of CF patients, they are not able to get rid of the pathogen. We thus want to better understand why neutrophils do not work properly and why they cannot protect CF patients from infections in the lung. Our discovery in adult CF patients of two new types of neutrophils in the circulation of adult CF patients may explain the persistent infections. We found an increase in one of these neutrophil types in CF patients that have a decline in lung function linking these cells to the disease. More research is needed to find out if these cells can kill pathogens to understand their role in CF. We also observed these new types of neutrophils in Trikafta-treated patients. Trikafata may thus not correct the CFTR defect in neutrophils and offer patients complete protection from infection. 1) We will study the function of the new types of neutrophils we found in adult CF patients with tests that we use in the laboratory. Their functions will be compared to neutrophils of healthy donors. Functional tests include the ability of producing toxic molecules to kill microbes. 2) We started a study on CF patients before Trikafta treatment on the function of neutrophils. We will also perform the functional tests on these patients' neutrophils after starting their Trikafata treatment. We will compare neutrophil function before and after starting Trikafta. We will also develop a novel cell model that will allow us to study the effect of this drug on neutrophils with additional tests that will provide more information on how the drug works. This project is relevant to the mission of the Lung Association as it addresses two gaps in our knowledge of CF. First, our findings will improve our understanding of the disease by providing insight into the function of the new types of neutrophils we discovered in adult CF patients. In addition, these neutrophils are potential biomarkers of disease severity and response to treatment. Second, our Trikafta fmdings will provide new information on whether this drug corrects the neutrophil defects in CF which is key to optimize disease management. New knowledge of the disease process in CF and the effect of a drug on the immune system will be important contributions to improving lung disease management in CF.
Programme
Canadian Lung Association Research Studentship
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
476985
Name
Murru Andrea
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Lung Association (Ottawa)
Prcname2
Special Cases
Projecttitle
Functional characterization of neutrophils in cystic fibrosis: clinical implications
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Canadian Lung Association Research Studentship
Keyworddelim
Cell Biology; Cystic Fibrosis; Elexacaftor-Tezacaftor-Ivacaftor; Inflammation; Neutrophil Sub-Populations
Abstract
Our findings will provide much needed knowledge on an aspect of CF that is not well understood. It will improve our understanding of CF by revealing how the two new types of neutrophils we discovered could be involved in the disease. Also, this research will provide information about how the new drug Trikafta affects the ability of neutrophils to function which is important to fight lung infections in CF. Cystic fibrosis (CF) is the most common fatal genetic disease in children and adults in Canada. It is caused by a change in a region of our genetic material called CFTR. This change affects the CFTR protein that our body needs to make thin and slippery fluids in the lung and other organs, and increases the chances of lung infections. Another reason why CF patients suffer from lung infections is that one of the cells of our body that fights infection does not work properly. We call this cell the neutrophil. These cells are sent to the lung in large numbers during an infection to eliminate the pathogen. While these cells go to the lung of CF patients, they are not able to get rid of the pathogen. We thus want to better understand why neutrophils do not work properly and why they cannot protect CF patients from infections in the lung. Our discovery in adult CF patients of two new types of neutrophils in the circulation of adult CF patients may explain the persistent infections. We found an increase in one of these neutrophil types in CF patients that have a decline in lung function linking these cells to the disease. More research is needed to find out if these cells can kill pathogens to understand their role in CF. We also observed these new types of neutrophils in Trikafta-treated patients. Trikafata may thus not correct the CFTR defect in neutrophils and offer patients complete protection from infection. 1) We will study the function of the new types of neutrophils we found in adult CF patients with tests that we use in the laboratory. Their functions will be compared to neutrophils of healthy donors. Functional tests include the ability of producing toxic molecules to kill microbes. 2) We started a study on CF patients before Trikafta treatment on the function of neutrophils. We will also perform the functional tests on these patients' neutrophils after starting their Trikafata treatment. We will compare neutrophil function before and after starting Trikafta. We will also develop a novel cell model that will allow us to study the effect of this drug on neutrophils with additional tests that will provide more information on how the drug works. This project is relevant to the mission of the Lung Association as it addresses two gaps in our knowledge of CF. First, our findings will improve our understanding of the disease by providing insight into the function of the new types of neutrophils we discovered in adult CF patients. In addition, these neutrophils are potential biomarkers of disease severity and response to treatment. Second, our Trikafta fmdings will provide new information on whether this drug corrects the neutrophil defects in CF which is key to optimize disease management. New knowledge of the disease process in CF and the effect of a drug on the immune system will be important contributions to improving lung disease management in CF.
Competitiondate
202210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Murru, Andrea
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Circ &Respiratory Hlth~ $17,500~ $0~